Samsung Bioepis is expanding operations in mainland China through a licensing agreement with C-Bridge Capital. The agreement covers multiple biosimilar candidates from Samsung Bioepis, including third-wave biosimilar candidates SB11 and SB12, which reference Lucentis (ranibizumab) and Soliris (eculizumab), respectively, as well as SB3, a biosimilar candidate referencing Herceptin 3 (trastuzumab).   Under the agreement, C-Bridge will establish a new biopharmaceutical company, AffaMed Therapeutics...